Jpmorgan Chase & CO Jounce Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	BUY	$0.9 - $1.85 $29,052 - $59,718	32,280 Added 2.92%	1,136,847 $2.1 Million
Q1 2023 May 11, 2023	BUY	$0.9 - $1.85 $768,923 - $1.58 Million	854,359 Added 341.46%	1,104,567 $2.04 Million
Q4 2022 Feb 13, 2023	BUY	$0.64 - $1.99 $90 - $280	141 Added 0.06%	250,208 $278,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $28,673 - $51,674	-10,503 Reduced 4.03%	250,067 $585,000
Q2 2022 Aug 11, 2022	BUY	$2.8 - $7.67 $101,320 - $277,546	36,186 Added 16.13%	260,570 $790,000
Q1 2022 May 11, 2022	SELL	$6.01 - $8.54 $237,449 - $337,406	-39,509 Reduced 14.97%	224,384 $1.52 Million
Q4 2021 Feb 10, 2022	SELL	$7.11 - $9.64 $202,862 - $275,048	-28,532 Reduced 9.76%	263,893 $2.2 Million
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $1.47 Million - $2.55 Million	292,425 New	292,425 $2.17 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.